BOP-CISCA-POMB-ACE regimen

a chemotherapy protocol consisting of the above cpds for the treatment of non-seminomatous germ cell tumors

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Therapy Context: Research Results

Therapeutics: 1158551
- Drug Therapy: 293145
  - Combination Drug Therapy: 12066
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - BOP-CISCA-POMB-ACE regimen: 1
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - BOP-CISCA-POMB-ACE regimen: 1
- Clinical Protocols
  - Antineoplastic Protocols: 55
    - Antineoplastic Combined Chemotherapy Protocols: 35
      - BOP-CISCA-POMB-ACE regimen: 1
Carbohydrates: 22023
- Glycosides: 2119
  - Aminoglycosides: 5131
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        BOP-CISCA-POMB-ACE regimen: 1
  - Glucosides: 639
    - Etoposide: 10706
      - BOP-CISCA-POMB-ACE regimen: 1
- Glycoconjugates: 1353
  - Glycopeptides: 1928
    - Bleomycin: 9833
      - BOP-CISCA-POMB-ACE regimen: 1
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Glycopeptides: 1928
    - Bleomycin: 9833
      - BOP-CISCA-POMB-ACE regimen: 1
  - Cyclic Peptides: 530
    - Dactinomycin: 2073
      - BOP-CISCA-POMB-ACE regimen: 1
Inorganic Chemicals: 9
Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Aromatic Hydrocarbons: 291
      - Polycyclic Aromatic Hydrocarbons: 2020
        Naphthalenes: 18
        Tetrahydronaphthalenes: 1
        Podophyllotoxin: 562
        Etoposide: 10706
        BOP-CISCA-POMB-ACE regimen: 1
        Naphthacenes
        Anthracyclines: 9423
        Daunorubicin: 2641
        Doxorubicin: 35390
        BOP-CISCA-POMB-ACE regimen: 1
  - Halogenated Hydrocarbons: 42
    - Mustard Compounds: 3
      - Nitrogen Mustard Compounds: 2
        Phosphoramide Mustards: 5
        Cyclophosphamide: 25473
        BOP-CISCA-POMB-ACE regimen: 1
- Organophosphorus Compounds: 300
  - Phosphoramides: 8
    - Phosphoramide Mustards: 5
      - Cyclophosphamide: 25473
        BOP-CISCA-POMB-ACE regimen: 1
Heterocyclic Compounds: 198
- Alkaloids: 5398
  - Indole Alkaloids: 200
    - Secologanin Tryptamine Alkaloids: 81
      - Vinca Alkaloids: 463
        Vincristine: 9251
        BOP-CISCA-POMB-ACE regimen: 1
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
  - 3-Ring Heterocyclic Compounds
    - Dactinomycin: 2073
      - BOP-CISCA-POMB-ACE regimen: 1
Polycyclic Compounds: 6
- Polycyclic Aromatic Hydrocarbons: 2020
  - Naphthalenes: 18
    - Tetrahydronaphthalenes: 1
      - Podophyllotoxin: 562
        Etoposide: 10706
        BOP-CISCA-POMB-ACE regimen: 1
  - Naphthacenes
    - Anthracyclines: 9423
      - Daunorubicin: 2641
        Doxorubicin: 35390
        BOP-CISCA-POMB-ACE regimen: 1
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - Dactinomycin: 2073
      - BOP-CISCA-POMB-ACE regimen: 1

Experts

1.	Amato, R J: 1 article (05/2002)
2.	Daliani, D: 1 article (05/2002)
3.	Do, K-A: 1 article (05/2002)
4.	Finn, L: 1 article (05/2002)
5.	Fizazi, K: 1 article (05/2002)
6.	Kim, J: 1 article (05/2002)
7.	Logothetis, C J: 1 article (05/2002)
8.	Millikan, R E: 1 article (05/2002)
9.	Pagliaro, L C: 1 article (05/2002)
10.	Papandreou, C N: 1 article (05/2002)

Related Diseases

1.	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 05/20/2002 - "The dose-dense BOP-CISCA-POMB-ACE regimen is highly active in patients with non-seminomatous germ-cell tumours classified as intermediate-prognosis or poor-prognosis according to the International Germ-Cell Cancer Consensus Group. "